Dewpoint Therapeutics Inc. and Chemify Ltd. have partnered to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed stimulator of interferon genes protein (STING; TMEM173) modulators reported to be useful for the treatment of cancer, infections and autoimmune disease.
Research at MUSC Foundation for Research Development has led to the identification of small molecules targeting the voltage-dependent anion channel (VDAC) NADH binding pocket.
Researchers from the University of Oxford and Oxstem Ltd. have discovered small-molecule candidates with the ability to induce differentiation of acute myeloid leukemia (AML) cells.
Pancreatic ductal adenocarcinoma (PDAC) is an exocrine pancreatic cancer with a poor prognosis and limited treatment options. There is a strong demand for new treatment strategies to overcome these challenges.
Riana Therapeutics GmbH, a spin-off from Vetmeduni Vienna founded this year, has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC) to support its efforts to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).
ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.
Eikon Therapeutics Inc. has received IND clearance from the FDA to initiate phase I studies with IMP-1734, a highly selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor developed in partnership with Impact Therapeutics Inc.
RSS
